{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:57Z","timestamp":1788184617438,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13104-015-1429-9","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T20:20:47Z","timestamp":1442866847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ingenol mebutate treatment in keloids"],"prefix":"10.1186","volume":"8","author":[{"given":"Bruna","family":"De Felice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Nacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"1429_CR1","first-page":"45","volume":"40","author":"B Fidler","year":"2014","unstructured":"Fidler B, Pharm D, Goldberg T. Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. Pharm D, BCPS Pharm Ther. 2014;40:45\u20136.","journal-title":"Pharm D, BCPS Pharm Ther"},{"key":"1429_CR2","author":"JS Kelsey","year":"2014","unstructured":"Kelsey JS, Geczy T, Lewin NE, Kedei N, Hill CS, Selezneva JS, Valle CJ, Woo W, Gorshkova I, Blumberg PM. Charge density influences C1 domain ligand affinity and membrane interactions. ChemBioChem. 2014;. doi: 10.1002\/cbic.201400041 .","journal-title":"ChemBioChem"},{"key":"1429_CR3","first-page":"1181","volume":"11","author":"M Stahlhut","year":"2012","unstructured":"Stahlhut M, Bertelsen M, Hoyer-Hansen M, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012;11:1181\u201392.","journal-title":"J Drugs Dermatol"},{"key":"1429_CR4","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1158\/0008-5472.CAN-09-4303","volume":"70","author":"L Li","year":"2010","unstructured":"Li L, Shukla S, Lee A, et al. The skin cancer chemotherapeutic agent ingenol- 3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010;70:4509\u201319.","journal-title":"Cancer Res"},{"key":"1429_CR5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/jid.2011.418","volume":"132","author":"SJ Cozzi","year":"2012","unstructured":"Cozzi SJ, Ogbourne SM, James C, Rebel HG, de Gruijl FR, Ferguson B, Gardner J, Lee TT, Larcher T, Suhrbier A. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2012;132:1263\u201371.","journal-title":"J Invest Dermatol"},{"key":"1429_CR6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11010-009-0057-x","volume":"327","author":"B Felice De","year":"2009","unstructured":"De Felice B, Garbi C, Santoriello M, Santillo A, Wilson RR. Differential apoptosis markers in human keloids and hypertrophic scars fibroblasts. Mol Cell Biochem. 2009;327:191\u2013201.","journal-title":"Mol Cell Biochem"},{"key":"1429_CR7","author":"B Felice De","year":"2009","unstructured":"De Felice B, Wilson RR, Nacca M. Telomere shortening may be associated with human keloids. BMC Med Genet. 2009;. doi: 10.1186\/1471-2350-10-110 .","journal-title":"BMC Med Genet"},{"key":"1429_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/dna.2007.0591","volume":"26","author":"B Felice De","year":"2007","unstructured":"De Felice B, Ciarmiello LF, Mondola P, Damiano S, Seru R, Argenziano C, Nacca M, Santoriello M, Garbi C. Differential p63 and p53 expression in human keloid fibroblasts and hypertrophic scar fibroblasts. DNA Cell Biol. 2007;26:541\u20137.","journal-title":"DNA Cell Biol"},{"key":"1429_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00438-004-1034-4","volume":"272","author":"B Felice De","year":"2004","unstructured":"De Felice B, Wilson RR, Nacca M, Ciarmiello LF, Pinelli C. Molecular characterization and expression of p63 isoforms in human keloids. Mol Genet Genomics. 2004;272:28\u201334.","journal-title":"Mol Genet Genomics"},{"key":"1429_CR10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygeno.2011.02.009","volume":"97","author":"B Felice De","year":"2011","unstructured":"De Felice B, Garbi C, Wilson RR, Santoriello M, Nacca M. Effect of selenocystine on gene expression profiles in human keloid fibroblasts. Genomics. 2011;97:265\u201376.","journal-title":"Genomics"},{"key":"1429_CR11","author":"E Marmur","year":"2014","unstructured":"Marmur E, Anderson L, Welburn P, Katsamas J. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 2014;. doi: 10.1007\/s13555-014-0059-9 .","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1429_CR12","author":"LJ Broek van den","year":"2014","unstructured":"van den Broek LJ, Limandjaja GC, Niessen FB, Gibbs S. Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissue engineering perspective. Exp Dermatol. 2014;. doi: 10.1111\/exd.12419 .","journal-title":"Exp Dermatol"},{"key":"1429_CR13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2119\/molmed.2009.00153","volume":"17","author":"GG Gauglitz","year":"2011","unstructured":"Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17:113\u201325.","journal-title":"Mol Med"},{"key":"1429_CR14","first-page":"1291","volume":"33","author":"B Berman","year":"2007","unstructured":"Berman B, Perez OA, Konda S, Kohut BE, Viera MH, Delgado S, Zell D, Li Q. A review of the biologic effects, clinical efficacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol Surg. 2007;33:1291\u2013302.","journal-title":"Dermatol Surg"},{"key":"1429_CR15","first-page":"23","volume":"6","author":"G Goldenberg","year":"2013","unstructured":"Goldenberg G, Luber AJ. Use of intralesional cryosurgery as an innovative therapy for keloid scars and a review of current treatments. J Clin Aesthet Dermatol. 2013;6:23\u20136.","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-015-1429-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T15:56:58Z","timestamp":1498233418000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1756-0500\/8\/466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1186\/s13104-015-1429-9","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]},"article-number":"466"}}